Anselamimab CARES Trial Failed Primary Endpoint
The clinical program did not meet its primary endpoint in patients with advanced cardiac-stage light-chain amyloidosis.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Should clinical trial success be measured by results for specific genetic subgroups rather than entire populations?
The CARES clinical program has failed to achieve a statistically significant improvement in its primary composite endpoint for adults with advanced cardiac-stage light-chain amyloidosis. While the overall study population did not see significant benefit, researchers noted substantial improvements in a specific kappa light-chain subgroup.
Why it matters
The study sought to determine if removing protein fibrils via anselamimab could improve survival and health outcomes in patients suffering from the rare condition of light-chain amyloidosis. These results highlight a complex response to the treatment, suggesting it may be more effective for patients based on their specific protein light-chain type.
In the kappa subgroup, anselamimab was associated with a 62% reduction in all-cause mortality and a 71% reduction in cardiovascular hospitalization risk. Grade 3 adverse events occurred at 80.4% in the treatment arm compared to 84.3% in the placebo group.
The details
The program evaluated anselamimab at a dosage of 1000 mg/m administered intravenously to patients alongside chemotherapy. Despite the primary endpoint failure, researchers observed a 0.80 hazard ratio for mortality and a 0.67 rate ratio for cardiovascular hospitalizations across the broad study group.
Timeline
September 2026: The research findings were presented at the SOHO meeting.
The Big Picture
The findings from the CARES clinical program mark a departure from initial efficacy expectations for amyloidosis therapy as researchers re-evaluate the impact of protein-clearing agents. This shift underscores the growing necessity for precision medicine in targeting specific disease subtypes like kappa versus lambda amyloidosis.
Patients with light-chain amyloidosis may see shifts in how physicians prioritize specific treatments based on their subtype, specifically for those with kappa light-chain protein types. These results provide new guidance for clinical expectations regarding the drug's safety profile and potential limitations.
The takeaway
The varied outcomes between kappa and lambda subgroups demonstrate the critical role of molecular subtyping in modern clinical trials for amyloidosis. Patients and medical providers should use these findings to discuss whether existing, broader treatments are still the most viable pathway given the specific protein profile of the disease.
Further reading
For more information on similar research, visit our Heart Disease section.
Source note: This article includes information reported by Medscape.
Live Poll
Should clinical trial success be measured by results for specific genetic subgroups rather than entire populations?
